Response to Chemotherapy, Reexposure to Crizotinib and Treatment with a Novel ALK Inhibitor in a Patient with Acquired Crizotinib Resistance

Publisher： Karger

E-ISSN： 1423-0356|88|3|262-264

ISSN： 0025-7931

Source： Respiration, Vol.88, Iss.3, 2014-08, pp. : 262-264

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drug‐induced reduction in estimated glomerular filtration rate in patients with ALK‐positive non‐small cell lung cancer treated with the ALK inhibitor crizotinib

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 664-674

John Wiley & Sons Inc

Access to resources Recommend Favorite

Experience in Integrating ALK Testing and Crizotinib into the Routine Treatment of Patients with Non-Small Cell Lung Cancer

Oncology Research and Treatment, Vol. 36, Iss. 6, 2013-04 ,pp. : 342-347

Karger

Access to resources Recommend Favorite

Crizotinib in ALK⁺ inflammatory myofibroblastic tumors—Current experience and future perspectives

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 65, Iss. 4, 2018-04 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Partial Response to First-Line Crizotinib in an Elderly Male Patient with ROS1 Translocation-Positive Lung Cancer

Case Reports in Oncology, Vol. 9, Iss. 1, 2016-03 ,pp. : 158-163

Karger

Access to resources Recommend Favorite

Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion

Oncology, Vol. 91, Iss. 6, 2016-10 ,pp. : 348-353

Karger

Access to resources Recommend Favorite